Following promising clinical outcomes with CD19-CAR T therapy against hematological cancers, the implication of CAR T cell-based therapeutic approaches for the treatment of solid tumors, including brain tumor has sparked huge interest among the scientific community. This evidence concerns the gene CD19 and hematopoietic and lymphoid cell neoplasm.